BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer - BioXcel Therapeutics

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype.

Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium.
The trial is evaluating the combination of BXCL701 with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab).
SCNC Findings: In the evaluable patient cohort (n = 15), 5 (33%) patients achieved a composite response at the planned interim analysis.
In patients with measurable disease (n = 12), partial response was observed in 4 (33%) patients (3 confirmed responses), and the disease control rate was 58% (7 patients).
Also See: FDA Pushes Review Of BioXcel's Candidate For Agitation Associated With Neuropsychiatric Disorders.
Key Adenocarcinoma Findings: In the evaluable patient cohort (n = 29), 6 (21%) patients achieved a composite response.
In patients with measurable disease (n = 18), partial response was observed in 4 (22%) patients (3 confirmed responses), and the disease control rate was 83% (15 patients); all responders experienced a decrease in tumor size from baseline.
In the 29 patients who had at least 1 post-baseline prostate-specific antigen (PSA) measurement, the PSA50 was 17%, including five patients who showed a -100% to -57% PSA decrease.
From historical data, single-agent pembrolizumab showed an objective response rate of 3% to 5%, a disease control rate of 12%, and a PSA50 response of 6%.1
Price Action: BTAI shares closed at $17.59 on Monday.

BTAIBioXcel Therapeutics Inc

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.